Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T L Ng

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
BJUI Compass|April 27, 2022
Risk factors in the prediction of long-term patency of Resonance metallic ureteric stent in malignant ureteric obstructionBrian S H Ho, Peter K F Chiu, Wayne Lam, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 2019
HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinibY Wang, T Jiang, Z Qin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 25, 2019
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registryJ Mazieres, A Drilon, A Lusque, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
BJUI Compass|April 27, 2022
Risk factors in the prediction of long-term patency of Resonance metallic ureteric stent in malignant ureteric obstructionBrian S H Ho, Peter K F Chiu, Wayne Lam, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 2019
HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinibY Wang, T Jiang, Z Qin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 25, 2019
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registryJ Mazieres, A Drilon, A Lusque, et al.
Pageof 4